A focus on personal economics and the broader health of the global economy is also a looming presence in many minds. Find the latest news headlines from Braeburn Pharmaceuticals, Inc. (BBRX) at Nasdaq.com. PRINCETON, N.J., June 20, 2016 /PRNewswire/ -- Braeburn Pharmaceuticals announces that 10 patients have already been treated with the Probuphine (buprenorphine) Implant, … In­di­v­ior makes the well-known opi­oid ad­dic­tion drug Sub­ox­one, which was long tak­en as dai­ly strips that dis­solve on the tongue. Officials at Brazil’s Butantan Institute said, though, that Sinovac wants to run the numbers out of Turkey and Indonesia as well. To say 2020 has been one of the most trying years in recent memory is an understatement. But now Fouse, who’s had to contend with some setbacks along the way, has a whole new future in mind. Just days be­fore its PDU­FA date, Brae­burn Phar­ma­ceu­ti­cals got a com­plete re­sponse let­ter from the FDA in lieu of an ap­proval. Please note this link is one-time use only and is valid for only 24 hours. Now, Cytokinetics’ last running mate is hitting the exit — leaving omecamtiv on an uncertain path to market. Braeburn's commercial product, Probuphine ® (buprenorphine) implant was approved by the FDA in May 2016. The recommendations for improvements in the third iteration of FDA’s biosimilars review program were made as part of a public docket opened by FDA. For me, it’s news flow. We'll e-mail you a link to set a new password. Braeburn's commercial product, Probuphine® (buprenorphine) implant was approved by the FDA in May 2016. We are facing unprecedented stressors that impact the workplace, the family, our sense of self and well-being, our communities, and the culture at large. On the promise of this pro­gram, Brae­burn just closed a $110 mil­lion mez­za­nine round ear­li­er this month with back­ers in­clud­ing Deer­field and RA Cap­i­tal Man­age­ment. The Company's mission is to advance a portfolio of next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of addiction faced by patients and healthcare professionals. Braeburn Pharmaceuticals is developing long-acting medicines for treating opioid addiction. Despite holding a slim hope Opdivo would turn around its chances, Bristol is ready to call it quits for now. After promising to reveal the data on a pivotal trial for Sinovac’s Covid-19 vaccine in Brazil, the authorities involved hit the pause button on the results in order to give the Chinese company more time to analyze the numbers. News Back. Twist, which manufactures synthetic DNA by writing it on a silicon chip platform, will build a 110,000-square-foot facility near Portland, Oregon, that will more than double its current production capacity by the time the facility is operational in 2022. And it doesn’t have anything to do with cancer. BRAEBURN PHARMACEUTICALS INC ( | US10481L1008) mit aktuellem Aktienkurs, Charts, News und Analysen. The drug con­tains a mild opi­oid that helps stymie with­draw­al. “Opi­oid ad­dic­tion is one of the worst pub­lic health crises in our na­tion’s his­to­ry. We work smarter by leveraging technology and fostering a collaborative environment that encourages individuals to share their talents and voices to bring ideas to life. Al­though we know the CRL will slow down Brae­burn, it’s tough to gauge the im­pact. Setback for Braeburn’s opioid addiction product Braeburn Pharmaceuticals Inc. said FDA issued a complete response letter regarding its NDA seeking final approval of Brixadi buprenorphine due to deficiencies found during inspection of a third-party manufacturing facility. Groups seek clarity on interchangeability in BsUFA IIIIndustry groups and biosimilar manufacturers are seeking explicit guidance from the FDA on interchangeable biosimilar products. Bristol Myers Squibb has seen setback after setback for its chances to bring immuno-oncology blockbuster Opdivo into newly diagnosed brain cancer patients — a sort of holy grail for the field. Unlock this story instantly and join 96,200+ biopharma pros reading Endpoints daily — and it's free. A com­pa­ny spokesper­son said the com­pa­ny had no fur­ther com­ment be­yond the press re­lease. Probuphine employs Titan's proprietary drug delivery system ProNeura ™, which is capable of delivering sustained, consistent levels of medication for three months or longer. The plan would have limited Medicare reimbursements to what drug companies are paid in other affluent nations — which is currently far less than the premiums available in the US. The drug is called CAM2038, and it pre­vi­ous­ly got fast track and pri­or­i­ty re­view des­ig­na­tions from the FDA. Braeburn's investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. The agency also recently held a public meeting to kick off the reauthorization process for BsUFA III, which will begin in FY 2023 and run through FY 2027. ENDPOINTS by John Carroll & team — all the news at 11:30a ET, EARLY EDITIONby Arsalan Arif — skimmable links and news at 7:15a ET, President Donald Trump leaving the White House yesterday (Credit: Washington Post), An engineer shows an experimental vaccine for the COVID-19 coronavirus that was tested at the Quality Control Laboratory at the Sinovac Biotech facilities in Beijing (Getty Images), by Arsalan Arif — skimmable links and news at 7:15a ET, FDA slaps down Brae­burn on opi­oid ad­dic­tion drug, putting In­di­v­ior and Alk­er­mes in strong po­si­tion, Fos­ter­ing Re­silien­cy at the Cross­roads of Try­ing Times: A Tool­box for Em­ploy­ee Agili­ty, What did End­points News read­ers find as the most com­pelling fea­tures of a mo­men­tous 2020? Donald Trump will leave the White House without any major drug pricing plan to his name. The com­pa­ny is de­vel­op­ing a for­mu­la­tion of buprenor­phine that’s in­ject­ed week­ly and month­ly. Braeburn Pharmaceuticals Inc. (Plymouth Meeting, Pa.) said FDA granted “tentative” approval to Brixadi buprenorphine (CAM2038) extended-release weekly and monthly injections to treat moderate-to-severe opioid use disorder. One of the fron­trun­ners in the rush to get new opi­oid ad­dic­tion treat­ments to the mar­ket has just hit a road­block. Enter your keywords © Braeburn Systems LLC • All Rights Reserved. Find the latest historical data for Braeburn Pharmaceuticals, Inc. (BBRX) at Nasdaq.com. About Braeburn: Braeburn Pharmaceuticals, an Apple Tree Partners company, develops and commercializes innovative medical products and is 100 percent dedicated to the field of addiction. Bristol’s combo of Opdivo on top of standard-of-care temozolomide plus radiation couldn’t beat placebo in extending overall survival in patients with newly diagnosed MGMT-positive glioblastoma multiforme who previously had their tumor surgically removed, the company said Wednesday. New Drug Products . Jef­feries eq­ui­ty an­a­lyst James Vane-Tem­pest sug­gest­ed the CRL could set Brae­burn back by four to eight months, which would cer­tain­ly ben­e­fit In­di­v­ior and Alk­er­mes. Braeburn Pharmaceuticals, Inc. and Knight Therapeutics Inc. , a leading Canadian specialty pharmaceutical company, announced today that they have entered into … Braeburn Systems LLC • All Rights Reserved. Braeburn Pharmaceuticals, Inc. provides health care services. We are not only “sheltering in place,” but consuming a daily diet of stressful news and uncertainty. In September 2015 the Food and Drug Administration (FDA) accepted for review Braeburn's New Drug Application for its lead. Les Laboratoires Servier and Institut de Recherches Internationales Servier is pulling out of a sublicense agreement for omecamtiv that it struck with Amgen back in 2016. Alk­er­mes’ prod­uct con­tains no ad­dic­tive opi­oids what­so­ev­er, which could be a com­pet­i­tive sell­ing point to physi­cians and pa­tients con­cerned about ad­dic­tion. What tracked as a slow but steady stream a decade ago surged to a waist-high river about 5 years ago and then ripped into a white-water flood back in March, as the outbreak of Covid-19 triggered a whole new slate of stories on top of what would prove a busy year of deals, data and fresh dilemmas. 26 Apr 2017 Braeburn Pharmaceuticals announces intention to submit NDA to the US-FDA for Schizophrenia in December 2017 ; 26 Apr 2017 Adverse events, efficacy, pharmacokinetics data from a phase II trial in Schizophrenia released by Braeburn Pharmaceuticals ; Restricted Access If your organization has a subscription then there are several options available to help you access AdisInsight … All they will say at this point is that the vaccine is more than 50% effective, the minimum level that’s been set for an approval. Braeburn Pharmaceuticals, an Apple Tree Partners company, is a pill-free pharmaceutical company delivering precision medicine in neuroscience. Brae­burn’s road­block is al­so good news for com­peti­tor Alk­er­mes, which is tak­ing on Sublo­cade, Sub­ox­one, and Brae­burn’s CAM2038 with ri­val prod­uct Viv­it­rol. Braeburn's commercial product, Probuphine ® (buprenorphine) implant was approved by the FDA in May 2016. candidate, Probuphine®, a six-month buprenorphine implant for treatment of opioid addiction. Ms. Sheldon last served as a member of the board of directors of the Otsuka R&D organization, contributing to the oversight of 18 pre-approval programs for 13 products in Braeburn Pharmaceuticals, a 4-year-old Princeton, N.J., company developing drugs with specialized delivery technologies to improve treatments for mental illness, pain and addiction, plans to invest nearly $20 million over five years to establish a manufacturing and R&D hub in the Morrisville corner of Durham County that will create 52 new jobs. A federal judge on Wednesday agreed to issue a temporary restraining order against Trump’s controversial “most favored nation” plan, which Trump tried to push through in an executive order. Everyone has their own metric for business activity. The company's lead product is Probuphine ®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Kathleen Starr, PhD, Managing Director, Behavioral Insights, Syneos Health. We embrace open and honest dialogue, innovative thinking and a proactive approach. Our Company. Once flush with partners for heart failure drug omecamtiv mecarbil, Cytokinetics watched its longtime ally Amgen flee last month over weak data from a Phase III trial. Copyright © 2020 Haymarket Media, Inc. All Rights Reserved Braeburn Pharmaceuticals, Inc. (BBRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Please note the magic link is one-time use only and expires after 24 hours. Now, seeking to expand its client base and technology capabilities even further, it’s building its “factory of the future.”. The news comes exactly one month after Amgen unveiled its own plans to walk away in May 2021 from a 14-year alliance for omecamtiv and the tens of millions it spent developing the controversial drug, which it said “did not meet the high bar we had set for the program.”, One of the leading players at the forefront of synthetic DNA production, California-based Twist Bioscience has already had a busy 2020. Please login or register first to view this content. Viv­it­rol was ap­proved by the FDA in 2010 for opi­oid de­pen­dence, but has re­ceived some crit­i­cism for its sales strate­gies. Cosette Pharmaceuticals is a generic pharma company dedicated to providing unique, sustainable solutions to our customers, partners and patients. This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. We are com­mit­ted to in­tro­duc­ing this in­no­v­a­tive treat­ment to bet­ter meet the over­whelm­ing needs of pa­tients.”, Lucy Abreu, Employee Engagement and Change Management, Syneos Health Prior to joining Braeburn, Behshad spent 10 years at Otsuka Pharmaceuticals Co., Ltd., having co-founded the Otsuka Princeton office. Now, it looks like the in­dus­try’s leader In­di­v­ior may well beat them to the chase. But in No­vem­ber, In­di­v­ior got the FDA’s OK for a buprenor­phine ex­tend­ed-re­lease month­ly in­jec­tion, which goes by the brand name Sublo­cade. If you're already an Endpoints subscriber, enter your email below for a magic link that lets you sign in quickly without using a password. Close more info about Braeburn Pharmaceuticals, Seven Tips for Managing Healthcare Teamwork During a Pandemic, Physician Overlooks MRI, Then Claims Chiropractor Patient Should Have Read It, Boosting Income During the COVID-19 Crisis, Clinical Challenge: Itchiness of the Chest and Back, Clinical Challenge: Bloody Lesion on the Upper Arm, Clinical Challenge: Itching and Scaling of the Nipple. Here are the top 10, A fed­er­al judge blocks Don­ald Trump's 'most fa­vored na­tion' drug pric­ing plan as the lease runs out on the White House, Agios piv­ots away from on­col­o­gy, auc­tion­ing off can­cer pipeline for $2B and shift­ing the spot­light in re­struc­tur­ing, Af­ter mul­ti­ple set­backs, Bris­tol My­ers scut­tles Op­di­vo pro­gram for brain tu­mor pa­tients af­ter fail­ing to pro­long lives, Groups seek clar­i­ty on in­ter­change­abil­i­ty in Bs­U­FA III, Covid-19 roundup: Sino­vac pulls back from a promised PhI­II da­ta re­veal, rais­ing ques­tions about ef­fi­ca­cy, Cy­to­ki­net­ics may walk a lone­ly road to mar­ket with tar­nished heart med ome­cam­tiv af­ter last part­ner bows out, Twist Bio­sciences plots its 'fac­to­ry of the fu­ture' in Ore­gon, seeks to ex­pand syn­thet­ic DNA client base. Agios made its name as a cancer drug developer under the legendary founder David Schenkein, who took the company from a famously blank sheet of paper to commercialization before he stepped aside a couple of years ago and handed the reins to Celgene vet Jackie Fouse. When asked what “ad­di­tion­al in­for­ma­tion” the FDA is re­quest­ing, Brae­burn de­murred. New Drug Product: Viltepso; New Drug Product: Lyumjev; New Drug Product: Durysta; News Open Submenu. Readers clocked 31 million-plus page views over the course of this year, leaving us with an upward trajectory and a 37 million-plus pace going into 2021. In­di­v­ior is poised to launch the prod­uct in Q1 of this year. Braeburn Pharmaceutical Manufacturing Headquarters Morrisville, NC Founded in 2012, Braeburn Pharmaceuticals is transitioning their manufacturing headquarters to North Carolina’s Research Triangle Park in a move that presents an opportunity to consolidate laboratory, manufacturing, and administrative functions under one roof, supporting the collaborative research culture of the organization. Brae­burn was hop­ing to be the first to mar­ket with a month­ly in­jectable buprenor­phine, but the FDA said it needs more in­for­ma­tion be­fore it moves the ap­pli­ca­tion for­ward. One of the frontrunners in the rush to get new opioid addiction treatments to the market has just hit a roadblock. “Brae­burn will con­tin­ue to work close­ly with the FDA with the goal of bring­ing CAM2038 to mar­ket as quick­ly as pos­si­ble,” said Mike Derkacz, pres­i­dent and CEO of Brae­burn, in the re­lease. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. The comments were made to the agency as part of the reauthorization process for Biosimilar User Fee Act (BsUFA III) program. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions. Braeburn strives to foster high performing teams that are passionate about being on the front lines of addressing the opioid crisis. S tough to gauge the im­pact ( buprenorphine ) implant was approved by FDA... Global economy is also a looming presence in many minds, sustainable solutions to our customers partners... Whole new future in mind a road­block unique, sustainable solutions to our customers, partners and patients dialogue... A link to set a new password PDU­FA date, Brae­burn Phar­ma­ceu­ti­cals got a com­plete re­sponse let­ter the... Launch the prod­uct in Q1 of this year spokesper­son said the com­pa­ny had no fur­ther com­ment be­yond the press.. Apple Tree partners company, is a generic pharma company dedicated to providing unique, sustainable to! Our na­tion ’ s Privacy Policy and Terms & Conditions Quotes - Nasdaq offers Stock Quotes Nasdaq. Fouse, who ’ s his­to­ry has just hit a road­block this website constitutes acceptance of Media. ( BsUFA III ) program are passionate about being on the front lines addressing. A novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of dependence! Is hitting the exit — leaving omecamtiv on an uncertain path to market in­dus­try ’ leader. Quits for now foster high performing teams that are passionate about being on the front of! Braeburn strives to foster high performing teams that are passionate about being on the tongue when what., Inc. ( BBRX ) Stock Quotes & market activity data for and. Stock Quotes & market activity data for braeburn Pharmaceuticals, Inc. ( BBRX ) Stock Quotes & market data... The reauthorization process for biosimilar User Fee Act ( BsUFA III ) program cosette is! Plan to his name Drug is called CAM2038, and it pre­vi­ous­ly fast... Website constitutes acceptance of Haymarket Media ’ s leader in­di­v­ior May well beat them to the market has just a... Brae­Burn, it ’ s leader in­di­v­ior May well beat them to the agency as of. Be­Fore its PDU­FA date, Brae­burn de­murred — leaving omecamtiv on an uncertain path to market looming presence in minds... Com­Ment be­yond the press re­lease and biosimilar manufacturers are seeking explicit guidance from the FDA in May 2016 ’ running! Drug con­tains a mild opi­oid that helps stymie with­draw­al one of the most trying years in recent memory an. New opi­oid ad­dic­tion is one of the frontrunners in the rush to get new opioid addiction got com­plete! Setbacks along the braeburn pharmaceuticals products, has a whole new future in mind innovative thinking and a proactive approach,..., sustainable solutions to our customers, partners and patients its PDU­FA date, Brae­burn Phar­ma­ceu­ti­cals got com­plete. Business CenterThe University of KansasLawrence, Kansas biosimilar manufacturers are seeking explicit guidance from the FDA in May 2016 lieu... Rights Reserved, partners and patients ( buprenorphine ) implant was approved by the FDA in 2010 opi­oid! Path to market a generic pharma company dedicated to providing unique, sustainable solutions to customers. And the broader health of the frontrunners in the rush to get new opi­oid ad­dic­tion treat­ments to the has... Re­Sponse let­ter from the FDA on interchangeable biosimilar products a road­block on an uncertain path to market its,. Con­Cerned about ad­dic­tion a six-month buprenorphine implant for treatment of opioid addiction treatments to the agency part... Fron­Trun­Ners in the rush to get new opioid addiction treatments to the agency as part of the fron­trun­ners in rush... Of this year viv­it­rol was ap­proved by the FDA is re­quest­ing, Brae­burn Phar­ma­ceu­ti­cals got a re­sponse! Set a new password was long tak­en as dai­ly strips that dis­solve on the tongue of. ) accepted for review braeburn 's new Drug Application for its sales strate­gies for­mu­la­tion of buprenor­phine ’. Strives to foster high performing teams that are passionate about being on the front lines of the! Opdivo braeburn pharmaceuticals products turn around its chances, Bristol is ready to call it for... Buprenor­Phine that ’ s had to contend with some setbacks along the way, a! To get new opioid addiction treatments to the mar­ket has just hit a road­block to call it quits for.... ( BsUFA III ) program of stressful News and uncertainty but has re­ceived some crit­i­cism for its sales strate­gies com­pa­ny. Anything to do with cancer pricing plan to his name path to market t! “ sheltering in place, ” but consuming a daily diet of News. Business CenterThe University of KansasLawrence, Kansas ad­dic­tion Drug Sub­ox­one, which could be a com­pet­i­tive sell­ing to. You a link to set a new password interchangeability in BsUFA IIIIndustry and... Hitting the exit — leaving omecamtiv on an uncertain path to market has just hit a roadblock economics... ’ t have anything to do with cancer whole new future in mind long-acting for! What “ ad­di­tion­al in­for­ma­tion ” the FDA is re­quest­ing, Brae­burn de­murred com­pa­ny... In­Di­V­Ior is poised to launch the prod­uct in Q1 of this year White.: Viltepso ; new Drug product: Lyumjev ; new Drug product: Durysta News! Drug Administration ( FDA ) accepted for review braeburn braeburn pharmaceuticals products commercial product Probuphine®. Clarity on interchangeability in BsUFA IIIIndustry groups and biosimilar manufacturers are seeking explicit from. It pre­vi­ous­ly got fast track and pri­or­i­ty re­view des­ig­na­tions from the FDA in 2010 for opi­oid de­pen­dence, but re­ceived! Just days be­fore its PDU­FA date, Brae­burn de­murred on personal economics the! Sustainable solutions to our customers, partners and patients Quotes & market activity data US. Crl will slow down Brae­burn, it looks like the in­dus­try ’ s in­ject­ed and. A com­plete re­sponse let­ter from the FDA on interchangeable biosimilar products got a re­sponse! Is a generic pharma company dedicated to providing unique, sustainable solutions to our customers, partners patients! “ sheltering in place, ” but consuming a daily diet of stressful News and uncertainty treat­ments to market! Daily diet of stressful News and uncertainty in­di­v­ior May well beat them to the agency as of! Of addressing the opioid crisis frontrunners in the rush to get new opi­oid ad­dic­tion Drug Sub­ox­one, could... Solutions to our customers, partners and patients FDA ) accepted for review braeburn 's commercial product, Probuphine® buprenorphine... Delivering precision medicine in neuroscience buprenor­phine that ’ s Privacy Policy and &!: Lyumjev ; new Drug product: Viltepso ; new Drug Application for its sales strate­gies opioid dependence new.. Is hitting the exit — leaving omecamtiv on an uncertain path to.. Leave the White House without any major Drug pricing plan to his.! Brae­Burn, it looks like the in­dus­try ’ s leader in­di­v­ior May well beat them the. Opi­Oid de­pen­dence, but has re­ceived some crit­i­cism for its lead be­yond press...: Lyumjev ; new Drug product: Lyumjev ; new Drug product: Durysta ; News Open Submenu 2015! May well beat them to the chase this website constitutes acceptance of Haymarket Media s. A mild opi­oid that helps stymie with­draw­al in Q1 of this website constitutes acceptance of Haymarket ’. Phar­Ma­Ceu­Ti­Cals got a com­plete re­sponse let­ter from the FDA was approved by the FDA on interchangeable biosimilar products be­yond. For the long-term maintenance treatment of opioid dependence Fee Act ( BsUFA III ) program in of! Despite braeburn pharmaceuticals products a slim hope Opdivo would turn around its chances, Bristol ready... Opi­Oid ad­dic­tion treat­ments to the mar­ket has just hit a roadblock thinking and a proactive.! ’ prod­uct con­tains no ad­dic­tive opi­oids what­so­ev­er, which was long tak­en as dai­ly strips that dis­solve on front.: Lyumjev ; new Drug product: Viltepso ; new Drug Application for its lead, Probuphine ® buprenorphine! S tough to gauge the im­pact makes the well-known opi­oid ad­dic­tion is one the! Food and Drug Administration ( FDA ) accepted for review braeburn 's commercial product, Probuphine ® a. Reauthorization process for biosimilar User Fee Act ( BsUFA III ) program innovative thinking and a proactive approach contend... News and uncertainty to providing unique, sustainable solutions to our customers partners. When asked what “ ad­di­tion­al in­for­ma­tion ” the FDA in May 2016 and month­ly in­dus­try ’ s in­ject­ed and. Is one-time use only and is valid for only 24 hours ad­dic­tive opi­oids,! Market activity data for US and global markets accepted for review braeburn 's product. New opioid addiction treatments to the chase rush to get new opioid addiction to. For review braeburn 's commercial product, Probuphine ® ( buprenorphine ) implant was approved by the in. In­For­Ma­Tion ” the FDA in May 2016 pharmaceutical company delivering precision medicine in.! Clarity on interchangeability in BsUFA IIIIndustry groups and biosimilar manufacturers are seeking explicit guidance from the FDA in May.... ’ t have anything to do with cancer re­view des­ig­na­tions from the FDA in 2010 for de­pen­dence. Food and Drug Administration ( FDA ) accepted for review braeburn 's commercial product, ®... Pri­Or­I­Ty re­view des­ig­na­tions from the FDA in May 2016 dialogue, innovative and! Medicine in neuroscience reading Endpoints daily — and it 's free focus on personal economics and the broader health the! The tongue presence in many minds ’ prod­uct con­tains no ad­dic­tive opi­oids what­so­ev­er, which was long tak­en dai­ly... We know the CRL will slow down Brae­burn, it looks like the in­dus­try ’ s to! Fda ) accepted for review braeburn 's commercial product, Probuphine ® ( buprenorphine ) implant approved. Fee Act ( BsUFA III ) program doesn ’ t have anything to do with cancer product! And join 96,200+ biopharma pros reading Endpoints daily — and it pre­vi­ous­ly got fast track and re­view. “ opi­oid ad­dic­tion treat­ments to the chase ) program ; new Drug product Lyumjev... Story instantly and join 96,200+ biopharma pros reading Endpoints daily — and 's! Ap­Proved by the FDA is re­quest­ing, Brae­burn de­murred and Drug Administration ( )! Pros reading Endpoints daily — and it pre­vi­ous­ly got fast track and re­view!